Complete Filing Data
Artiva Biotherapeutics, Inc. reported Stockholders Equity of $109.97 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Artiva Biotherapeutics, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue * | $251.0K | $32.9M | |
| Net Income Loss | -$83.9M | -$65.4M | -$28.7M |
| Research And Development Expense | $69.5M | $50.3M | $50.3M |
| Other Nonoperating Income Expense | -$14.0K | $157.0K | $195.0K |
| Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent | -$437.0K | $308.0K | |
| Operating Income Loss | -$89.8M | -$67.3M | -$30.7M |
| Operating Expenses | $89.8M | $67.5M | $64.2M |
| Nonoperating Income Expense | $5.9M | $1.9M | $2.0M |
| General And Administrative Expense | $20.3M | $17.2M | $13.9M |
| Comprehensive Income Net Of Tax | -$83.6M | -$65.8M | -$28.4M |
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | $232.0K | -$437.0K | |
| Revenue Not From Contract With Customer | $0.00 | $251.0K | $569.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue * | $26.7M | $3.5M | |||||||
| Net Income Loss | -$21.5M | -$21.3M | -$20.3M | -$17.5M | -$17.8M | -$14.0M | $11.3M | -$11.3M | -$16.7M |
| Research And Development Expense | $17.6M | $17.9M | $17.1M | $13.5M | $12.3M | $11.2M | $13.1M | $11.3M | |
| Other Nonoperating Income Expense | -$3.0K | -$5.0K | -$4.0K | -$6.0K | $23.0K | $147.0K | $50.0K | $31.0K | |
| Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent | $2.0K | $129.0K | $217.0K | -$86.0K | -$101.0K | $144.0K | $127.0K | ||
| Operating Income Loss | -$22.9M | -$22.8M | -$22.2M | -$18.3M | -$16.2M | -$14.5M | $10.8M | -$11.8M | |
| Operating Expenses | $22.9M | $22.8M | $22.2M | $18.3M | $16.2M | $14.7M | $15.8M | $15.3M | |
| Nonoperating Income Expense | $1.4M | $1.6M | $1.9M | $863.0K | -$1.7M | $529.0K | $468.0K | $540.0K | |
| General And Administrative Expense | $5.3M | $4.9M | $5.1M | $4.8M | $3.9M | $3.6M | $2.8M | $4.1M | |
| Comprehensive Income Net Of Tax | -$21.4M | -$21.3M | -$20.2M | -$17.3M | -$17.9M | -$14.1M | $11.4M | -$11.2M | |
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | $85.0K | $2.0K | $129.0K | $217.0K | -$86.0K | -$101.0K | |||
| Revenue Not From Contract With Customer | $251.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Stockholders Equity | $110.0M | $186.6M | -$162.0M | -$140.7M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $27.2M | $40.5M | $53.8M | $102.8M |
| Restricted Cash Noncurrent | $461.0K | $258.0K | $258.0K | |
| Cash And Cash Equivalents At Carrying Value | $26.7M | $40.2M | $53.5M | |
| Short Term Investments | $81.3M | $145.2M | $23.5M | |
| Retained Earnings Accumulated Deficit | -$330.5M | -$246.7M | -$181.3M | |
| Property Plant And Equipment Net | $6.6M | $6.4M | $8.1M | |
| Prepaid Expense And Other Assets Current | $4.6M | $3.1M | $1.1M | |
| Other Receivables Net Current | $67.0K | $146.0K | $724.0K | |
| Other Assets Noncurrent | $458.0K | $267.0K | $392.0K | |
| Operating Lease Right Of Use Asset | $10.5M | $13.8M | $16.5M | |
| Operating Lease Liability Noncurrent | $7.9M | $10.6M | $13.3M | |
| Operating Lease Liability Current | $3.0M | $3.6M | $3.6M | |
| Liabilities Current | $13.1M | $12.3M | $12.2M | |
| Liabilities And Stockholders Equity | $130.9M | $209.6M | $105.1M | |
| Liabilities | $21.0M | $22.9M | $50.7M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$13.3M | -$13.3M | -$49.0M | |
| Assets Current | $112.7M | $188.6M | $79.8M | |
| Assets | $130.9M | $209.6M | $105.1M | |
| Additional Paid In Capital Common Stock | $440.4M | $433.5M | $19.0M | |
| Accrued Liabilities Current | $9.6M | $7.4M | $8.0M | |
| Accounts Payable Current | $355.0K | $1.1M | $614.0K | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | $103.0K | -$129.0K | $308.0K | |
| Accretion Amortization Of Discounts And Premiums Investments | $1.9M | $2.3M | $456.0K | |
| Finance Lease Right Of Use Asset | $212.0K | $261.0K | ||
| Finance Lease Liability Current | $44.0K | $122.0K | ||
| Other Liabilities Noncurrent | $73.0K | $73.0K | ||
| Finance Lease Principal Payments | $132.0K | $149.0K | ||
| Common Stock Value | $3.0K | $3.0K | ||
| Finance Lease Liability Noncurrent | $44.0K | |||
| Non Cash Additions To Finance Lease | $0.00 | $241.0K | ||
| Adjustment To Additional Paid In Capital Vesting Of Shares Of Common Stock Subject To Repurchase Including Early Exercise | 30.0K | |||
| Accounts Receivable Net Current | $0.00 | $1.0M | ||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | $442.0K | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $129.2M | $149.0M | $168.8M | $201.0M | -$191.1M | -$174.7M | -$151.5M | -$164.3M | -$155.6M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $26.0M | $28.9M | $30.9M | $56.1M | $34.5M | $48.5M | $66.1M | $54.0M | |
| Restricted Cash Noncurrent | $461.0K | $461.0K | $461.0K | $258.0K | $258.0K | $258.0K | $258.0K | $258.0K | |
| Cash And Cash Equivalents At Carrying Value | $25.5M | $28.5M | $30.4M | $55.9M | $34.2M | $48.2M | $65.9M | $53.7M | |
| Short Term Investments | $97.5M | $113.9M | $135.6M | $90.8M | $12.3M | ||||
| Retained Earnings Accumulated Deficit | -$309.8M | -$288.2M | -$267.0M | -$230.6M | -$213.1M | ||||
| Property Plant And Equipment Net | $7.0M | $6.9M | $7.1M | $6.9M | $7.3M | ||||
| Prepaid Expense And Other Assets Current | $6.5M | $6.7M | $3.8M | $3.2M | $1.7M | ||||
| Other Receivables Net Current | $79.0K | $30.0K | $234.0K | $132.0K | $892.0K | ||||
| Other Assets Noncurrent | $418.0K | $38.0K | $13.0K | $298.0K | $330.0K | ||||
| Operating Lease Right Of Use Asset | $11.3M | $12.7M | $13.5M | $14.4M | $15.1M | ||||
| Operating Lease Liability Noncurrent | $8.5M | $9.6M | $10.3M | $11.2M | $11.9M | ||||
| Operating Lease Liability Current | $3.1M | $3.5M | $3.6M | $3.6M | $3.7M | ||||
| Liabilities Current | $11.1M | $10.8M | $12.2M | $13.3M | $10.8M | ||||
| Liabilities And Stockholders Equity | $148.9M | $169.4M | $191.3M | $225.6M | $75.9M | ||||
| Liabilities | $19.6M | $20.4M | $22.5M | $24.6M | $50.6M | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$9.6M | -$5.3M | |||||||
| Assets Current | $129.5M | $149.1M | $170.0M | $150.6M | $49.7M | ||||
| Assets | $148.9M | $169.4M | $191.3M | $225.6M | $75.9M | ||||
| Additional Paid In Capital Common Stock | $438.9M | $437.3M | $435.8M | $431.2M | $21.9M | ||||
| Accrued Liabilities Current | $7.0M | $5.8M | $6.4M | $8.3M | $6.2M | ||||
| Accounts Payable Current | $848.0K | $1.2M | $2.0M | $1.2M | $823.0K | ||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $87.0K | $2.0K | $338.0K | $121.0K | |||||
| Accretion Amortization Of Discounts And Premiums Investments | $723.0K | $368.0K | |||||||
| Finance Lease Right Of Use Asset | $216.0K | $231.0K | $246.0K | $276.0K | $291.0K | ||||
| Finance Lease Liability Current | $75.0K | $106.0K | $126.0K | $119.0K | $116.0K | ||||
| Other Liabilities Noncurrent | $73.0K | $74.0K | |||||||
| Finance Lease Principal Payments | $33.0K | ||||||||
| Common Stock Value | $3.0K | $3.0K | $3.0K | $3.0K | |||||
| Finance Lease Liability Noncurrent | $11.0K | $75.0K | $106.0K | ||||||
| Non Cash Additions To Finance Lease | |||||||||
| Adjustment To Additional Paid In Capital Vesting Of Shares Of Common Stock Subject To Repurchase Including Early Exercise | 7.0K | 8.0K | 7.0K | ||||||
| Accounts Receivable Net Current | $569.0K | $569.0K | |||||||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | $442.0K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Share Based Compensation | $6.8M | $7.0M | $7.1M |
| Payments To Acquire Property Plant And Equipment | $2.6M | $642.0K | $3.3M |
| Net Cash Provided By Used In Operating Activities | -$76.8M | -$55.0M | -$47.4M |
| Net Cash Provided By Used In Investing Activities | $63.4M | -$120.5M | -$26.0M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $1.5M | $2.0M | -$516.0K |
| Increase Decrease In Other Receivables | -$79.0K | -$578.0K | $724.0K |
| Increase Decrease In Other Noncurrent Assets | $191.0K | -$125.0K | -$139.0K |
| Increase Decrease In Operating Leaseright Of Useasset And Lease Liabilities | -$21.0K | $43.0K | $145.0K |
| Increase Decrease In Accrued Liabilities | $2.0M | -$659.0K | -$912.0K |
| Increase Decrease In Accounts Payable | -$760.0K | $519.0K | -$408.0K |
| Depreciation Depletion And Amortization | $2.6M | $2.4M | $2.3M |
| Proceeds From Stock Options Exercised | $138.0K | $51.0K | $10.0K |
| Net Cash Provided By Used In Financing Activities | $9.0K | $162.2M | $24.4M |
| Increase Decrease In Accounts Receivable | $0.00 | -$1.0M | $510.0K |
| Proceeds From Sale Maturity And Collections Of Investments | $110.9M | $56.4M | |
| Payments To Acquire Investments | $44.9M | $176.2M | |
| Payments Of Stock Issuance Costs | $0.00 | $4.2M | |
| Proceeds From Purchase Of Employee Stock Purchase Plan Shares | -233.0K | 0.00 | |
| Proceeds From Issuance Of Common Stock | $0.00 | $166.5M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 |
|---|---|---|
| Share Based Compensation | $2.1M | $1.4M |
| Payments To Acquire Property Plant And Equipment | $511.0K | $18.0K |
| Net Cash Provided By Used In Operating Activities | -$19.8M | -$15.1M |
| Net Cash Provided By Used In Investing Activities | $10.0M | $9.8M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $750.0K | $936.0K |
| Increase Decrease In Other Receivables | $88.0K | $180.0K |
| Increase Decrease In Other Noncurrent Assets | -$254.0K | -$31.0K |
| Increase Decrease In Operating Leaseright Of Useasset And Lease Liabilities | -$13.0K | $45.0K |
| Increase Decrease In Accrued Liabilities | -$931.0K | -$3.0M |
| Increase Decrease In Accounts Payable | $41.0K | $851.0K |
| Depreciation Depletion And Amortization | $628.0K | $587.0K |
| Proceeds From Stock Options Exercised | $138.0K | |
| Net Cash Provided By Used In Financing Activities | $239.0K | |
| Increase Decrease In Accounts Receivable | -$215.0K | |
| Proceeds From Sale Maturity And Collections Of Investments | $29.0M | $16.0M |
| Payments To Acquire Investments | $18.5M | $6.2M |
| Payments Of Stock Issuance Costs | ||
| Proceeds From Purchase Of Employee Stock Purchase Plan Shares | -134.0K | |
| Proceeds From Issuance Of Common Stock |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 24.4M | 11.3M | 802.7K |
| Weighted Average Number Of Diluted Shares Outstanding | 24.4M | 11.3M | 802.7K |
| Earnings Per Share Diluted | $-3.43 | $-5.81 | $-35.78 |
| Earnings Per Share Basic | $-3.43 | $-5.81 | $-35.78 |
| Common Stock Shares Authorized | 700.0M | ||
| Common Stock Par Or Stated Value Per Share | $0.00 | ||
| Preferred Stock Shares Authorized | 10.0M | ||
| Common Stock Shares Issued | 424.0K | 424.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 24.5M | 24.4M | 24.3M | 18.9M | 811.2K | 809.8K | 806.7K | 800.9K |
| Weighted Average Number Of Diluted Shares Outstanding | 24.5M | 24.4M | 24.3M | 18.9M | 811.2K | 809.8K | 7.0M | 800.9K |
| Earnings Per Share Diluted | $-0.88 | $-0.87 | $-0.83 | $-0.92 | $-22.00 | $-17.24 | $1.62 | $-14.09 |
| Earnings Per Share Basic | $-0.88 | $-0.87 | $-0.83 | $-0.92 | $-22.00 | $-17.24 | $13.98 | $-14.09 |
| Common Stock Shares Authorized | 40.2M | |||||||
| Common Stock Par Or Stated Value Per Share | $0.00 | |||||||
| Preferred Stock Shares Authorized | ||||||||
| Common Stock Shares Issued | 424.0K | 424.0K | 424.0K | 424.0K |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $6.8M | $7.0M | $7.1M |
| Investment Income Net | $6.0M | $5.3M | $2.5M |
| Stock Issued During Period Value Stock Options Exercised | $138.0K | $51.0K | $10.0K |
| Capital Expenditures Incurred But Not Yet Paid | $292.0K | $57.0K | $18.0K |
| Unrealized Gain Loss On Derivatives | $0.00 | -$3.6M | -$707.0K |
| Stock Issued During Period Value Employee Stock Purchase Plan | $233.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $1.6M | $1.5M | $2.1M | $1.9M | $1.5M | $1.4M | $1.4M | $2.5M | $1.8M |
| Investment Income Net | $1.4M | $1.6M | $1.9M | $1.8M | $676.0K | $650.0K | $418.0K | $509.0K | |
| Stock Issued During Period Value Stock Options Exercised | $138.0K | $6.0K | $22.0K | $10.0K | |||||
| Capital Expenditures Incurred But Not Yet Paid | $882.0K | $13.0K | |||||||
| Unrealized Gain Loss On Derivatives | -$977.0K | -$2.4M | -$268.0K | ||||||
| Stock Issued During Period Value Employee Stock Purchase Plan | $99.0K | $134.0K |
Most recent annual filing with the SEC: March 10, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.